A tale of two alleles: TP53 and transformation in MPNs.

作者信息

Brierley Charlotte, Psaila Bethan

机构信息

University of Oxford.

Memorial Sloan Kettering Cancer Center.

出版信息

Blood. 2022 Jun 23;139(25):3567-3568. doi: 10.1182/blood.2022016490.

DOI:10.1182/blood.2022016490

PMID:35737408

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9227100/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8e6/9227100/a62b0a374c7e/bloodBLD2022016490Cf1.jpg

相似文献

A tale of two alleles: TP53 and transformation in MPNs.

Blood. 2022 Jun 23;139(25):3567-3568. doi: 10.1182/blood.2022016490.

Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

Mol Cancer Res. 2011 Mar;9(3):271-9. doi: 10.1158/1541-7786.MCR-10-0496. Epub 2011 Feb 22.

Tailoring Chemotherapy for the African-Centric S47 Variant of TP53.

Cancer Res. 2018 Oct 1;78(19):5694-5705. doi: 10.1158/0008-5472.CAN-18-1327. Epub 2018 Aug 16.

JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.

Leukemia. 2018 Aug;32(8):1842-1845. doi: 10.1038/s41375-018-0145-6. Epub 2018 Apr 24.

Mutant p53: it's not all one and the same.

Cell Death Differ. 2022 May;29(5):983-987. doi: 10.1038/s41418-022-00989-y. Epub 2022 Mar 31.

Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity.

Gynecol Oncol. 2009 Jul;114(1):18-25. doi: 10.1016/j.ygyno.2009.03.023. Epub 2009 Apr 16.

Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.

Sci Rep. 2019 Dec 2;9(1):18062. doi: 10.1038/s41598-019-54407-4.

Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.

Br J Haematol. 2017 Sep;178(5):824-826. doi: 10.1111/bjh.14172. Epub 2016 Jun 13.

Tumor suppressor protein p53 regulates megakaryocytic polyploidization and apoptosis.

J Biol Chem. 2008 Jun 6;283(23):15589-600. doi: 10.1074/jbc.M801923200. Epub 2008 Apr 8.

TP53 codon 72 polymorphism and type 2 diabetes: a case-control study in South Indian population.

Mol Biol Rep. 2021 Jun;48(6):5093-5097. doi: 10.1007/s11033-021-06505-8. Epub 2021 Jun 28.

引用本文的文献

JAK/STAT in leukemia: a clinical update.

Mol Cancer. 2024 Jan 26;23(1):25. doi: 10.1186/s12943-023-01929-1.

本文引用的文献

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation.

Blood. 2022 Jun 23;139(25):3630-3646. doi: 10.1182/blood.2021014465.

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

Lancet. 2021 Jan 23;397(10271):281-292. doi: 10.1016/S0140-6736(20)32554-X.

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

Blood Adv. 2020 Oct 13;4(19):4887-4897. doi: 10.1182/bloodadvances.2020002271.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Nat Med. 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z. Epub 2020 Aug 3.

Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Blood Adv. 2018 Dec 26;2(24):3581-3589. doi: 10.1182/bloodadvances.2018024018.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.

Oncogene. 2017 Jun 8;36(23):3300-3311. doi: 10.1038/onc.2016.478. Epub 2017 Jan 9.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5401-10. doi: 10.1073/pnas.1407792111. Epub 2014 Dec 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr
超能文献

A tale of two alleles: TP53 and transformation in MPNs.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr超能文献

A tale of two alleles: TP53 and transformation in MPNs.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr
超能文献